Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DCTH Delcath Systems	$14.84 +3.4%	$12.29	$5.30 ▼ $16.97	$496.15M	0.72	367,208 shs	940,903 shs
NPCE NeuroPace	$12.89 +2.7%	$11.51	$5.45 ▼ $15.11	$422.19M	2.04	133,066 shs	188,035 shs
SGHT Sight Sciences	$3.10 +2.3%	$2.67	$2.03 ▼ $8.45	$160.26M	2.41	211,149 shs	233,672 shs
SMLR Semler Scientific	$34.79 -1.3%	$35.13	$21.03 ▼ $81.56	$333.88M	1.33	424,226 shs	489,693 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DCTH Delcath Systems	+23.60%	+18.79%	+38.11%	-11.69%	+160.20%
NPCE NeuroPace	+4.02%	+6.45%	+13.06%	-4.34%	-0.40%
SGHT Sight Sciences	+5.94%	-1.62%	+44.98%	+9.39%	-45.41%
SMLR Semler Scientific	+6.85%	+5.96%	+10.46%	-28.22%	+67.93%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DCTH Delcath Systems	2.7557 of 5 stars	3.5	3.0	2.5	2.5	0.6
NPCE NeuroPace	2.9232 of 5 stars	2.4	5.0	2.7	4.2	0.6
SGHT Sight Sciences	3.639 of 5 stars	4.1	3.0	2.5	4.2	0.6
SMLR Semler Scientific	3.2874 of 5 stars	3.5	3.0	3.3	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DCTH Delcath Systems	3.00	Buy	$22.75	53.30% Upside
NPCE NeuroPace	2.80	Moderate Buy	$15.20	17.92% Upside
SGHT Sight Sciences	2.29	Hold	$3.92	26.34% Upside
SMLR Semler Scientific	3.00	Buy	$71.00	104.08% Upside

Current Analyst Ratings Breakdown

Latest SGHT, DCTH, NPCE, and SMLR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/9/2025	SGHT Sight Sciences	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$2.50 ➝ $3.00
4/9/2025	SGHT Sight Sciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
3/7/2025	DCTH Delcath Systems	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$22.00 ➝ $24.00
3/6/2025	SGHT Sight Sciences	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$3.00 ➝ $2.50
3/6/2025	SGHT Sight Sciences	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
3/6/2025	SGHT Sight Sciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.50 ➝ $3.50
3/6/2025	SGHT Sight Sciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
3/5/2025	NPCE NeuroPace	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$19.00 ➝ $20.00
3/4/2025	SGHT Sight Sciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.60 ➝ $3.00

(Data available from 5/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DCTH Delcath Systems	$37.21M	13.34	N/A	N/A	$0.72 per share	20.61
NPCE NeuroPace	$79.91M	5.28	N/A	N/A	$0.79 per share	16.32
SGHT Sight Sciences	$79.87M	2.01	N/A	N/A	$2.47 per share	1.26
SMLR Semler Scientific	$56.29M	5.93	$2.05 per share	16.95	$10.45 per share	3.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DCTH Delcath Systems	-$47.68M	-$0.98	N/A	N/A	N/A	-150.70%	-338.16%	-104.02%	N/A
NPCE NeuroPace	-$32.96M	-$0.95	N/A	N/A	N/A	-36.74%	-205.41%	-28.29%	5/14/2025 (Estimated)
SGHT Sight Sciences	-$55.55M	-$1.03	N/A	N/A	N/A	-63.30%	-47.28%	-32.72%	N/A
SMLR Semler Scientific	$20.58M	$4.91	7.09	∞	N/A	72.65%	50.77%	47.04%	5/13/2025 (Estimated)

Latest SGHT, DCTH, NPCE, and SMLR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	NPCE NeuroPace	-$0.26	N/A	N/A	N/A	$21.85 million	N/A
5/8/2025	Q1 2025	DCTH Delcath Systems	$0.10	$0.03	-$0.07	$0.03	$16.83 million	N/A
5/8/2025	Q1 2025	SGHT Sight Sciences	-$0.29	-$0.28	+$0.01	-$0.28	$16.51 million	$17.51 million
3/6/2025	Q4 2024	DCTH Delcath Systems	-$0.10	-$0.11	-$0.01	-$0.11	$14.96 million	$15.10 million
3/5/2025	Q4 2024	SGHT Sight Sciences	-$0.22	-$0.23	-$0.01	-$0.23	$18.98 million	$19.07 million
3/4/2025	Q4 2024	NPCE NeuroPace	-$0.25	-$0.18	+$0.07	-$0.18	$21.14 million	$21.47 million
2/18/2025	Q4 2024	SMLR Semler Scientific	$0.20	$3.41	+$3.21	$3.41	N/A	$12.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DCTH Delcath Systems	N/A	N/A	N/A	N/A	N/A
NPCE NeuroPace	N/A	N/A	N/A	N/A	N/A
SGHT Sight Sciences	N/A	N/A	N/A	N/A	N/A
SMLR Semler Scientific	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DCTH Delcath Systems	N/A	1.34	1.03
NPCE NeuroPace	6.03	5.59	4.77
SGHT Sight Sciences	0.36	10.18	9.74
SMLR Semler Scientific	N/A	3.14	3.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DCTH Delcath Systems	61.12%
NPCE NeuroPace	78.83%
SGHT Sight Sciences	55.51%
SMLR Semler Scientific	49.37%

Insider Ownership

Company	Insider Ownership
DCTH Delcath Systems	17.40%
NPCE NeuroPace	22.20%
SGHT Sight Sciences	28.90%
SMLR Semler Scientific	30.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DCTH Delcath Systems	60	33.43 million	26.24 million	Optionable
NPCE NeuroPace	170	32.75 million	23.22 million	Optionable
SGHT Sight Sciences	210	51.70 million	36.09 million	Optionable
SMLR Semler Scientific	120	9.60 million	6.47 million	Not Optionable

SGHT, DCTH, NPCE, and SMLR Headlines

Recent News About These Companies

Insider Decision Unfolding At Semler Scientific: Douglas Murphy-Chutorian Exercises Options, Resulting In $0

May 6 at 4:22 PM | benzinga.com

Semler Scientific Quietly Builds One of the Top Bitcoin Treasuries

May 6 at 6:38 AM | crypto-news-flash.com

Stifel Financial Corp Has $2.82 Million Stock Holdings in Semler Scientific, Inc. (NASDAQ:SMLR)

May 6 at 3:51 AM | marketbeat.com

Semler Scientific Buys 167 More BTC, Now One Of The Largest Bitcoin Treasury Holders In U.S.

May 5, 2025 | bitcoinmagazine.com

Semler Scientific Adds 167 Bitcoins to Treasury, Total Reaches 3,634 BTC

May 5, 2025 | news.bitcoin.com

Raymond James Financial Inc. Purchases New Shares in Semler Scientific, Inc. (NASDAQ:SMLR)

May 4, 2025 | marketbeat.com

Bitcoin tops $97K as institutional demand and state reserves rise

May 3, 2025 | msn.com

Semler Scientific Buys Additional $15.7 Million Worth of Bitcoin

May 1, 2025 | bitcoinmagazine.com

Semler Scientific is back with fresh $15.7M, 165 BTC purchase, BTC Yield at 23.8% YTD

May 1, 2025 | cryptopolitan.com

Semler Scientific® Announces Updated BTC & ATM Activity; Purchased Additional 165 BTC; Now Holds 3,467 BTC; YTD BTC Yield of 23.8%; Earnings Release Date and Conference Call for First Quarter 2025 Financial Results

April 30, 2025 | prnewswire.com

Invesco Ltd. Acquires New Shares in Semler Scientific, Inc. (NASDAQ:SMLR)

April 28, 2025 | marketbeat.com

Miller Value Partners LLC Purchases Shares of 43,000 Semler Scientific, Inc. (NASDAQ:SMLR)

April 27, 2025 | marketbeat.com

Semler Scientific reports bitcoin holdings and ATM offering progress

April 27, 2025 | investing.com

Semler Scientific acquired 111BTC for $100M since February 14

April 26, 2025 | markets.businessinsider.com

Why Semler Scientific, Inc.’s (SMLR) Stock Is Up 6.33%

April 26, 2025 | aaii.com

Semler Scientific Pushes Bitcoin Stack to Over 3,300 BTC With $10M Buy

April 25, 2025 | coindesk.com

Semler Scientific® Announces Updated BTC & ATM Activity; Purchased Additional 111 BTC; Now Holds 3,303 BTC; YTD BTC Yield of 23.5%

April 25, 2025 | prnewswire.com

Susquehanna Advisors Group Inc. Makes New Investment in Semler Scientific, Inc. (NASDAQ:SMLR)

April 24, 2025 | marketbeat.com

Semler Scientific, Inc. (NASDAQ:SMLR) Short Interest Update

April 23, 2025 | marketbeat.com

Capital International Investors Invests $30.81 Million in Semler Scientific, Inc. (NASDAQ:SMLR)

April 23, 2025 | marketbeat.com

Wells Fargo & Company MN Has $5.59 Million Position in Semler Scientific, Inc. (NASDAQ:SMLR)

April 21, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGHT, DCTH, NPCE, and SMLR Company Descriptions

Delcath Systems NASDAQ:DCTH

$14.84 +0.49 (+3.41%)

As of 04:00 PM Eastern

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

NeuroPace NASDAQ:NPCE

$12.89 +0.34 (+2.71%)

As of 04:00 PM Eastern

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Sight Sciences NASDAQ:SGHT

$3.10 +0.07 (+2.31%)

As of 03:57 PM Eastern

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.

Semler Scientific NASDAQ:SMLR

$34.79 -0.45 (-1.28%)

As of 04:00 PM Eastern

Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time